Quality-control surveys inrecent years, in venous parts of the world, have shown poor between-laboratoryagreement for measurements of plasma proteins. Despite the existence of international reference materials distributed by the World Health Organization, standards produced by diagnostics manufacturers and professionalorganizationsdiffer significantly in theirascnbedvalues. The reasons for this are complex but indude poor availability of the primary matenals, confusionabout their use, and the fact that their turbidity on reconstitution precludes their use in modem optical immunoassays. This unfortunate situation led to an important initiative to produce sufficient quantities of a widely available, optically dear secondary reference material for plasma proteins that could be used worldwide by manufacturers, professional organizations,and laboratories. Here we present an overview on how the laboratorycommunity,includingmanufacturers,clinicallaboratories, professional societies, and regulators, has reached what we consideris a successfulconclusionto a difficultproblem.
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Preparationof RPPHS
Extensive testing of the procedures to be used for the final lot of the RPPHS was undertaken with several pilot batches. These procedures were shown to result in a very clear material that could be used in all common methods of immunoassay. Aclerated degradation studies showed no significant change in protein concentration in samples of the lyophilized material stored at 45C#{176} for 1 year. All procedures and data for the final lot were documented in detail to permit the reproduction of similar material when a new lot is needed (10). The steps in preparation were as follows: 1) Fresh serum, derived from naturally clotted whole blood (-175 mL per donor), was collected from several hundred healthy individuals in five European cities. So that a similar donor pool could be assembled in the future, demographic data for each donor were recorded, including country of origin, race, age, gender, weight, and blood group.
2) The individual collections were tested for H1V-1 and -2, HTLV-1, hepatitis B surface antigen, and hepatitis C antibody, with test materials approved by the US Food and Drug Administration, Washington, DC. They were also tested for the presence of rheumatoid factor, monoclonal immunoglobulins, and other abnormalities identifiable by serum electrophoresis.
Phenotyping was performed for a1-antitrypsin and haptoglobin. The individual collections were examined for hemolysis, hyperbilirubinemia, and turbidity. All collections that showed abnormalities or possible interfering substances were excluded.
3) The collections were preserved by the addition of sodium azide, then frozen and shipped to the central processing center. The individual collections were thawed, pooled, and delipidated with fumed microparticulate silicon dioxide, and then stabilized with additiotial sodium azide, aprotinin, and benzamidine. Pure C-reactive protein was added to a final concentration of -40 mg(L. The material was buffered to pH 7.2, and subjected to sterile ifitration. Vials were filled with 1.00 mL of the material, freeze-dried, and sealed.
Value Assignments
Analyses for value assignment were performed by 27 laboratories in Europe, the US, and Japan, according to a rigorous protocol designed to test the appropriateness of the candidate preparation as well as the performance of the collaborating laboratories (Table 1) . Multiple dilutions of the RPPHS and of the relevant primary reference materials were made, such that all assays were within the same assay range for both materials. Linearity over the range of assays and regression through zero were required (11) to ensure similar behavior of the materials (i.e., absence of matrix effect differences) and lack of antigen excess. The slopes of the regression lines were used to assign the values. A trial exercise in value assignment clearly showed greatly improved precision if all reconstitutions and dilutions were weight-corrected with a sensitive balance. Therefore, all reconstitutions and manual dilutions used in the value assignment were done in this way.
The values assigned to the RPPHS in some cases significantly differ from those in previous reference materials, except for RPSP-4 (currently available from CAP).'#{176} The most significant changes from the mass values assigned to RPSP-2 and RPSP-3 involve transthyretin, a1-acid glycoprotein, a1-antitrypsin, and 1gM. These changes range from 10% to 40%. In addition, the relationships of mass values to IU are different in the RPPHS, because the IU values were assigned directly against WHO materials rather than against USNRP.
The evidence from the value assignment exercise sug-'#{176}However, referenced against RPPHS, the values assigned to RPSP-4 for a1-antitrypsin and tranathyretin should be -10%
higher (assigned values, 1.60 and 0.26 g/L, respectively; referenced against RPPHS, 1.75 and 0.28 g/L, respectively).
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